Results 151 to 160 of about 93,853 (343)

A Probabilistic Generative Grammar for Semantic Parsing [PDF]

open access: gold, 2017
Abulhair Saparov   +2 more
openalex   +1 more source

Increased Medial Posterior Tibial Slope Associated With Ramp Lesion Healing Failure After All‐Inside Device Repair in Anterior Cruciate Ligament Reconstruction: A Second‐Look Arthroscopic Study

open access: yesArthroscopy, EarlyView.
Purpose To assess the healing status of ramp lesions repaired using all‐inside devices via second‐look arthroscopy and to identify risk factors associated with healing failure. Methods This study reviewed patients treated between 2016 and 2022 who underwent primary anterior cruciate ligament (ACL) reconstruction with concurrent ramp lesion treatment ...
Hiroaki Fukushima   +10 more
wiley   +1 more source

Impact of evolving treatment patterns on interstitial lung disease progression in systemic sclerosis using the EUSTAR database

open access: yesArthritis &Rheumatology, Accepted Article.
Background The treatment landscape for systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) has evolved with increasing immunosuppressive (IST) and anti‐fibrotic therapies available. However, their real‐world use remains unclear. Objectives To analyze treatment trends and the effect of IST and anti‐fibrotic therapies on ILD progression ...
Corrado Campochiaro   +17 more
wiley   +1 more source

Glucagon‐Like Peptide 1 Receptor Agonists, Sodium‐Glucose Cotransporter 2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases

open access: yesArthritis &Rheumatology, EarlyView.
Objective Glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) and sodium‐glucose cotransporter 2 inhibitors (SGLT2i) facilitate weight loss and exhibit immunomodulatory effects, but their impact on the risk of developing autoimmune rheumatic diseases (ARDs) is unclear.
Derin Karacabeyli   +4 more
wiley   +1 more source

Single‐cell level characterization of B cell depletion and repopulation following rituximab in systemic lupus erythematosus

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Rituximab, a CD20+ B cell depletion therapy, is frequently used to treat systemic lupus erythematosus (SLE). However, variability in patient response highlights the need for a deeper understanding of the underlying immune cell dynamics of B cell depletion and repopulation.
Haerin Jang   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy